eft ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor

• Conditions: Patients with severe aortic valve stenosis treated with Aortic Valve Replacement (AVR)

• Registration Number: EUCTR2005-001930-34-DK
• Lead Sponsor: Department of Cardiology, Odense University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11-25
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion criteria
1.Symptomatic severe AVS referred for valve replacement (mechanic prosthesis or bioprosthesis) at Odense University Hospital
2.Age > 18 years
3.Signed informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion criteria
1.Severe renal failure (s-creatinine >300 mmole/l)
2.Moderate or severe hepatic failure (ALAT >150 IU/l)
3.Moderate or severe LV systolic dysfunction (LVEF<40%)
4.Known intolerance for angiotensin II receptor antagonist (Atacand)
5.Unwilling to participate in the study
6.Poor echocardiographic window
7. Women of childbearing potential (only postmenopausal women)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified